Chronic Graft Versus Host Disease (cGVHD) Consortium

Download Profile PDF
At a Glance
  • Status: Active Consortium
  • Year Launched: 2009
  • Initiating Organization: NIH Rare Disease Clinical Research Network
  • Initiator Type: Government
  • Rare disease
  • Disease focus:
    Immune Related Disorders After Allogenic Hematopoietic Cell Tran
  • Location: North America

Abstract

The Chronic Graft Versus Host Disease (cGVHD) Consortium is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in different immune-mediated disorders after allogeneic hematopoietic cell transplantation and to improving the care of patients affected by these disorders.

Mission

The cGVHD Consortium seeks to decrease illness, limit disability and prevent death for patients who develop immune-mediated complications after allogeneic hematopoietic cell transplantation.

Goals of the consortium are as follows:

Structure & Governance

This consortium is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS). The RDCRN is designed to advance medical research on rare diseases by providing support for clinical studies and facilitating collaboration, study enrollment, and data sharing. Through the RDCRN consortia, physician scientists and their multidisciplinary teams work together with patient advocacy groups to study more than 200 rare diseases at sites across the nation.

Funding and scientific oversight for the RDCRN are provided by NCATS and 10 National Institutes of Health (NIH) components: Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Heart, Lung and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; and Office of the Director. In addition, patient advocacy groups provide funds for many of the projects.

Financing

Funded by NIH, the cGVHD Consortium is part of the RDCRN.

Impact/Accomplishment

Chronic Graft versus Host Disease Projects:

6501: Longitudinal Study of Immune Mediated Disorders after Allogeneic HCT Protocol (Immune Mediated Disorders after Allo-HCT)

6504: A Phase II Study of Bandage Lenses for Ocular Graft-versus-host Disease after Allogeneic Hematopoietic Cell Transplantation

Cutaneous Sclerosis

6502: A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation

Bronchiolitis Obliterans

6503: Targeted Therapy of Bronchiolitis Obliterans Syndrome (BOS)

Points of Contact

chronicGVHDstudies@fhcrc.org

Sponsors & Partners

Cleveland Clinic

Dana Farber Cancer Institute

Fred Hutchinson Cancer Research Center

H. Lee Moffitt Cancer Center

Mayo Clinic, Scottsdale, AZ

Medical College of Wisconsin

National Cancer Institute

Roswell Park Cancer Center

Stanford University

University of Minnesota

University of North Carolina

Vanderbilt University

Washington University, St. Louis

Weill Cornell Medical College

Last Updated: 04/14/2016
The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.
Register your consortium  
All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.